Cramer: Apple Is Th...
Health Care: Drugs
Allos Therapeutics Inc. (ALTH: NASDAQ)
$1.77 -0.01 | -0.56%
06/01/12 - 04:00 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -30.53M | -77.42M | -73.55M | -51.73M |
| Operating Gains/Losses | 0.00 | 207.00K | 309.00K | 570.39K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -3.16M | -7.93M | -3.39M | -167.85K |
| (Increase) Decrease in Inventories | -329.00K | -102.00K | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -3.43M | 2.77M | 1.69M | -911.32K |
| (Decrease) Increase In Other Current Liabilities | -1.69M | 4.31M | 3.45M | 1.91M |
| (Increase) Decrease In Other Working Capital | 25.33M | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 11.58M | 11.56M | 8.68M | 8.02M |
| Net Cash From Continuing Operations | -752.00K | -63.66M | -62.20M | -42.85M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -752.00K | -63.66M | -62.20M | -42.85M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 70.28M | 41.98M | 53.39M | 81.88M |
| Purchases of Property, Plant & Equipment | -82.00K | -1.02M | -7.21M | -1.10M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | -74.97M | -18.21M | -93.94M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | -54.30K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 39.90M | -34.01M | 27.97M | -13.21M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 173.00K | 4.64M | 144.95M | 70.59M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -113.00K | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 60.00K | 4.64M | 144.95M | 70.59M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 39.21M | -93.02M | 110.73M | 14.54M |
Portfolios with ALTH
- Portfolio NameUser Type
- UserSaveyn walter
- ContributorStocks Under-$10 Setting Up...
- Userrab 's
- Usergdean1
- User$5 stocks
- UserStocks Under $5
- UserLegal Tender II
- UserTop Picks Under $5 for 2011...
- ContributorTop Stock Picks Under $5 fo...
- UserWatch List - Healthcare / B...
Latest ALTH Headlines from TheStreet
- Monday's Top 10 Articles, Videos on TheStreet 04.09.12 | 03:04 pm
- Spectrum Pharma: The Growth Party is Over 04.09.12 | 06:04 am
- Allos Stock Gaps Down On Today's Open (ALTH) 01.20.12 | 09:01 am
- Biotech Stock Mailbag: Amarin, Spectrum, Arena 01.06.12 | 06:01 am
- Spectrum Pharmaceuticals CEO: "We Are Always Looking for the Diamond in the Rough."
12.01.11 | 06:12 am - Next Step for Amag's Board: Fire CEO, Sell the Company. 10.21.11 | 11:10 am
- Biotech Stock Mailbag: Keryx Pharma 10.14.11 | 06:10 am
- Activist Fund Manager Ups Stake in Amag Pharma to Stop Merger With Allos 10.10.11 | 10:10 am
- Spectrum Pharma Said to Make Bid for Allos 09.21.11 | 11:09 am
- Biotech Stock Mailbag: Vivus 09.16.11 | 05:09 am
Press Releases for ALTH
- Allos Therapeutics (Graphic: Business Wire) - Business Wire 05.24.12 | 07:05 pm
- Spectrum Pharmaceuticals And Allos Therapeutics Announce Extension Of Previously Announced Tender Offer For Shares Of Allos Therapeutics - Business Wire 05.10.12 | 07:05 am
- Spectrum Pharmaceuticals Commences Tender Offer For All Outstanding Shares Of Allos Therapeutics - Business Wire 04.16.12 | 08:04 am
- Allos Therapeutics, Inc. (ALTH) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Spectrum Pharmaceuticals - PR Newswire 04.05.12 | 10:04 am
- Spectrum Pharmaceuticals To Acquire Allos Therapeutics: Acquisition Expected To Be Accretive On A Cash Basis In Q4 Of 2012 - Business Wire 04.05.12 | 07:04 am
- Allos Therapeutics Reports Fourth Quarter And Full Year 2011 Financial Results - Business Wire 03.06.12 | 04:03 pm
- Allos Therapeutics To Report Fourth Quarter And Full Year 2011 Results On March 6, 2012 - Business Wire 02.21.12 | 08:02 am
- Allos Therapeutics Requests Re-Examination Of CHMP Opinion On FOLOTYN® In PTCL At The European Medicines Agency - Business Wire 01.30.12 | 08:01 am
- Allos Therapeutics Announces Interim Results From Phase 1 Combination Study Of FOLOTYN® And Bexarotene Demonstrate Activity In Patients With Relapsed Or Refractory Cutaneous T-cell Lymphoma - Business Wire 01.30.12 | 08:01 am
- Allos Therapeutics Receives Negative Opinion From The CHMP On FOLOTYN - Business Wire 01.20.12 | 07:01 am
Partner Headlines for ALTH
- Company News for April 9, 2012 - Corporate Summary - Zacks 04.09.12 | 10:04 am
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Benzinga's M&A Chatter for Thursday April 5, 2012 - Benzinga 04.08.12 | 01:04 pm
- Futures Steer Lower; Spectrum Pharmaceuticals Dives - Investor's Business Daily 04.05.12 | 09:04 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 03.30.12 | 09:03 am
- Allos Narrows Loss - Analyst Blog - Zacks 03.07.12 | 09:03 am
- ALTH Seeks Review of Folotyn Verdict - Analyst Blog - Zacks 02.06.12 | 06:02 pm
- Loss Shrinks at AMAG, CEO Departs - Analyst Blog - Zacks 11.08.11 | 10:11 am
- Company News for November 4, 2011 - Corporate Summary - Zacks 11.04.11 | 10:11 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.25.11 | 09:10 am
